Morepen Laboratories slumped 6.07% to Rs 47.95 after the company reported 10% fall in consolidated net profit to Rs 21.52 crore despite a 29% rise in net income from operations to Rs 396.49 crore in Q3 FY22 over Q3 FY21.
Total expenditure increased by 30% YoY to Rs 372.05 crore during the quarter, due to higher raw material costs (up 23% YoY), higher selling and distribution expenses (up 162% YoY), higher power and fuel charges (up 44% YoY) and higher travelling expenses (up 38% YoY).
Profit before tax in Q3 FY22 stood at Rs 27.13 crore, up by 14% from Rs 23.80 crore reported in Q3 FY21. The company recorded a current tax outgo of Rs 5.61 crore during the period under review.
Morepen Laboratories is a pharmaceutical and healthcare products company. It is a leading manufacturer of high-quality APIs, home diagnostics, formulations and OTC products in north India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
